Novo Nordisk Announces Encouraging Data From REACH Real-World Study, Stock Up

(RTTNews) - Novo Nordisk A/S (NVO), Thursday announced findings from the REACH real-world study, evaluating the cardiovascular disease-related outcomes of the once-weekly GLP-1 RA class, compared to glucose-lowering therapies.

The study, involving nearly 60,000 US Medicare patients, demonstrated that compared to dulaglutide, Ozempic was associated with a reduced risk of major adverse cardiovascular events such as a heart attack or stroke by 23 percent.

Additionally, the findings showed that once-weekly semaglutide was also associated with a 25 percent risk reduction of heart attack, stroke, hospitalization for unstable angina or heart failure, and death from any cause.

Currently, NVO is trading at $61.49, up 5.66 percent on the New York Stock Exchange.